All In Biotech

Drug Trial Radar · NCT03586427

Zelquistinel in the Treatment of Major Depressive Disorder

A Double-Blind, Placebo-Controlled, Fixed-Dose Study of AGN-241751 in Adult Participants With Major Depressive Disorder

Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

251

Actual

Start

Jun 13, 2018

Primary completion

Jul 22, 2019

Study completion Aug 21, 2019

Sponsor

Lead sponsor
Syndeio Biosciences, IncIndustry
Sponsor type
Industry
First posted
Jul 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).

Conditions

  • Depressive Disorder, Major

Interventions

  • AGN-241751Drug

    AGN-241751 administered orally as a single tablet

  • PlaceboDrug

    Placebo administered orally as a single tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline to Day 1

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Health Initiatives Research PLLC

    Fayetteville, Arkansas

  • Synexus US - Cerritos

    Cerritos, California

  • Wake Research - Pharmacology Research Institute

    Encino, California

  • Wake Research - Pharmacology Research Institute

    Newport Beach, California

  • Pacific Research Partners, LLC

    Oakland, California

  • North County Clinical Research, Inc.

    Oceanside, California

  • Collaborative Neuroscience Network

    Torrance, California

  • Elite Clinical Trials, Inc.

    Wildomar, California

  • Synexus US - Atlanta

    Atlanta, Georgia

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • Pillar Clinical Research

    Lincolnwood, Illinois

  • Boston Clinical Trials

    Boston, Massachusetts

  • Hassman Research Institute

    Berlin, New Jersey

  • Center for Emotional Fitness

    Cherry Hill, New Jersey

  • Neurobehavioral Research, Inc

    Cedarhurst, New York

  • Synexus US - Queens

    Jamaica, New York

  • Eastside Comprehensive Medical Center

    New York, New York

  • Finger Lakes Clinical Research

    Rochester, New York

  • Neuro-Behavioral Clinical Research, Inc

    North Canton, Ohio

  • IPS Research

    Oklahoma City, Oklahoma

  • Clinical Neuroscience Solutions, Inc - Memphis, TN

    Memphis, Tennessee

  • Research Strategies of Memphis, LLC

    Memphis, Tennessee

  • Donald J. Garcia, Jr., MD, PA

    Austin, Texas

  • FutureSearch Trials of Dallas, LP

    Dallas, Texas

  • Northwest Clinical Research Center

    Bellevue, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.